Sutro Biopharma (STRO) Earnings Date & Reports

Key Takeaways

• Sutro Biopharma is expected to report its third-quarter 2026 results (quarter ended September 30, 2026) on November 11, 2026.
• Analyst consensus calls for a net loss of roughly $1.66 per share, compared with a loss of $0.67 per share in the same quarter last year.
• Consensus revenue stands near $13.61 million, up about 40% from the $9.69 million reported a year ago.
• Investors will focus on clinical updates for STRO-004 and other ADC (antibody drug conjugate) programs, plus the company's cash runway.
• The company missed EPS expectations in its most recent report, posting a $2.33 per-share loss versus the $2.19 consensus estimate.
• For more on STRO's Major News, Today's Price Move, Price Targets, and Forecast, visit the dedicated pages for additional detail.
• Explore Trending AI Robots to see AI-driven trading strategies currently gaining traction in the market.

Earnings Context and Why It Matters

Sutro Biopharma is a clinical-stage oncology company that develops next-generation antibody drug conjugates (ADCs) — a class of medicines designed to deliver a cancer-killing agent directly to tumor cells while sparing healthy tissue. Because the company does not yet have an approved product, its quarterly results are driven less by sales and more by collaboration revenue, clinical milestones, and research and development spending. For investors, each earnings release is a key checkpoint on pipeline progress and capital efficiency. With shares trading well below their 52-week high and the company having missed consensus in its last report, the upcoming update will be closely watched for signals on STRO-004's clinical trajectory and how far current cash can fund operations.

Earnings Expectations

Wall Street's consensus for the third quarter of 2026 calls for a net loss of approximately $1.66 per share, a notable widening from the $0.67 per-share loss reported in the third quarter of 2025. Revenue is expected to come in around $13.61 million, which would represent roughly 40% year-over-year growth from $9.69 million. As a pre-revenue biotech, Sutro's top line is largely collaboration-driven, so investors will watch the composition and timing of milestone payments rather than raw revenue alone.

The company's recent track record has been uneven. In the second quarter of 2026, Sutro reported a $2.33 per-share loss, missing the $2.19 consensus estimate, while revenue of $9.84 million fell short of the $11.96 million analysts had projected. In the first quarter of 2026, it posted a $2.94 loss per share but beat revenue expectations with $14.52 million. Beyond the headline numbers, the market will focus on updates to the STRO-004 Phase 1 study and management's guidance on operating expenses and cash runway, which are central to how long the company can sustain development without additional financing.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening, saving time while surfacing signals that might otherwise be overlooked. For investors following earnings-driven moves in names like Sutro Biopharma, the AI Screener offers a structured way to narrow the market to relevant candidates.

Market Reaction and Investor Sentiment

Sentiment heading into the report remains cautious. Sutro Biopharma's stock has been volatile around recent earnings, falling roughly 15% the day after its second-quarter release in August 2026 following the EPS miss. With shares trading near the lower end of their 52-week range, the market appears to be pricing in execution risk around the pipeline and ongoing cash burn. Key risk factors ahead of the release include any delays in clinical timelines, weaker-than-expected collaboration revenue, and uncertainty around future financing needs. Conversely, a positive clinical update on STRO-004 or better-than-expected expense discipline could shift sentiment. Because the company's valuation is heavily tied to pipeline catalysts rather than near-term earnings, investors will likely react more to clinical and strategic disclosures than to the raw EPS figure itself.

Forward Outlook and Key Factors to Monitor

Following the earnings release, investors should pay attention to several forward-looking themes. First is the clinical progress of STRO-004, Sutro's most advanced wholly owned ADC candidate. Any data updates, enrollment milestones, or regulatory feedback will be the most direct drivers of the investment narrative.

Second is the company's cash position and spending trajectory. As a clinical-stage biotech with no marketed products, Sutro relies on its balance sheet and collaboration revenue to fund research and development. Management's commentary on operating expense trends and cash runway will signal whether additional capital raises may be needed and on what timeline.

Third is the partnership revenue outlook. Sutro's collaboration agreements, including its ADC platform licensing relationships, generate milestone-based revenue that can be lumpy from quarter to quarter. Investors will want clarity on the timing and size of expected milestone payments.

Finally, broader industry dynamics in oncology and the ADC space remain relevant, as competition and deal activity can influence how the market values early-stage programs. Monitoring these factors together — rather than any single headline number — will offer the clearest read on the company's direction after the report.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations